The sharpest way to understand Deborah Bitterfield's company is not to begin with a molecule. Begin with a Tuesday. Somewhere on it sits an appointment, travel in both directions and an administration process that can command hours. The medicine may be sophisticated. The calendar is brutally ordinary. Bitterfield, a materials scientist who became a founder, has spent the better part of a decade working on a microscopic subtraction that could alter that arithmetic: take out the water.
At Lindy Biosciences, the company she founded in 2017, protein-containing droplets are dehydrated into dense microparticles. Those particles can be suspended in a non-aqueous vehicle and designed to flow through a fine needle. The aim is to fit a high dose of a biologic into a small volume suitable for a quick subcutaneous administration. It is particle engineering presented as time engineering.
Bitterfield calls the platform Microglassification. The name evokes tiny chandeliers; the real object is more workmanlike. Remove water quickly, keep the protein stable in a dry state, then formulate the resulting particles into a ready-to-use suspension. Concentrated liquid proteins can become inconveniently viscous. Bitterfield's favorite plain-English comparison is honey through a needle. Dry particles in an oily vehicle behave differently. They can remain dense without asking the liquid itself to carry an impossible concentration.
The scientist in the exact right room
This is not a founder's tale about wandering into an industry and declaring it ripe for disruption. Bitterfield earned her PhD in materials science at Duke University, with a focus on biomaterials, from 2005 to 2011. Her research took place in David Needham's laboratory, where the underlying dehydration technique was invented. She published work on the hydration potential of lysozyme and protein dehydration using a single-microparticle technique. The company story begins where the dissertation ended.
After graduation, Southeast TechInventures hired her as principal investigator on work connected to an $800,000 Small Business Innovation Research grant with the Duke lab. The first commercial proposition was preservation: could the technique help keep biologics stable? A few industry collaborations supplied the more valuable clue. The platform appeared to have a larger opportunity in high-concentration delivery.
That turn matters. Laboratory inventions are often described as if their commercial destiny were visible from the first clean result. Here, the use case improved through contact with partners. Preservation was a credible question. Delivery was the sharper problem. Bitterfield and Neil Jones, who was consulting with Southeast TechInventures and would become Lindy's vice president of corporate strategic partnerships, followed the evidence and spun out a company.
“If I had known everything then that I've learned in the past few years, it would have been a quicker and easier road. But it's also possibly not quite as fun.”Deborah Bitterfield, on building Lindy
A startup financed one proof at a time
Lindy did not arrive with a cinematic cheque and a battalion of employees. A $200,000 business research loan from the North Carolina Biotechnology Center, paired with a small convertible note, served as seed financing. Bitterfield has credited that early capital with carrying the company to its first partners and its Series A. In 2019, Lindy announced a $1.6 million round and had six full-time employees. By 2022 it had raised another multimillion-dollar round and was preparing to expand its team and facility.
Fundraising taught Bitterfield the unromantic lesson first-time CEOs learn in public. Every round took longer than she expected. Convincing investors meant communicating a clear vision while asking them to believe she could execute without a long chief-executive history. Later, she described the continuing tradeoff just as plainly: raising money consumes time that would otherwise go toward running the company.
Her answer was a chain of proof rather than a louder pitch. Stability data. Preclinical work. Pharmaceutical collaborations. A team capable of formulation development. Partners for what the team should not build itself. Lindy chose Lifecore Biomedical to support process development, scale-up and clinical manufacturing at a GMP line in Minnesota. The small company could stay focused on formulation while a specialist handled the manufacturing bridge.
The deal, and the discipline behind it
In August 2024, Lindy and Novartis announced a global licensing and collaboration agreement covering multiple molecular targets. The disclosed economics included $20 million upfront and as much as $934 million in potential regulatory, development and commercial milestone payments, plus tiered single-digit royalties. Numbers that large tend to swallow the story around them. The more instructive fact is structural: a major pharmaceutical company licensed a small platform company's formulation approach across several targets.
Bitterfield's public explanation remained grounded in the format rather than the fortune. Novartis would bring molecules and global development capability. Lindy would bring a way to condense high doses into small volumes. The individual products are undisclosed. The ambition is concrete: move the technology into the clinic through collaborators and gather the first human data.
Partnership is not decoration on Lindy's model. It is the model's connective tissue. Bitterfield has spent years speaking at formulation and drug-delivery meetings, while Jones built relationships across the pharmaceutical industry. In a 2022 industry panel, Bitterfield joined executives from large drugmakers to discuss how innovators and pharma can scope, structure and negotiate collaborations. The company's path makes a persuasive footnote: earn attention with a physical solution, then make yourself dependable enough to share a development program.
Her publication record helps explain that dependability. It stretches from early studies of protein dehydration and microsphere behavior to a 2016 model of how solutes dissolve from microdroplets and a 2023 comparison of Microglassification with lyophilization using a monoclonal antibody. The subjects are technical, but the progression is readable: understand what water does around a protein, understand what happens when a droplet changes state, then test whether the engineered dry form holds up against an established method. The founder's biography and the platform's evidence have grown along the same axis.
“We're trying to change the rhythm of patient care by giving patients easier access to the medications they need.”Deborah Bitterfield, 2026
The Research Triangle as borrowed scale
Lindy grew in North Carolina's Research Triangle, where universities, experienced pharmaceutical operators, investors and manufacturing knowledge are close enough to become an informal extension of a young company. Bitterfield has said that access to expertise is easier there than it might be elsewhere. Lindy recruited interns from neighboring universities and assembled leaders with experience across product development, quality, finance, partnerships and clinical manufacturing.
For a founder, this is more than hometown affection. It is a capital strategy. Every seasoned adviser prevents an avoidable mistake. Every nearby technical hire shortens a search. Every institution willing to fund the unglamorous interval between paper and product makes sophisticated science a little more financeable. Lindy used the region as borrowed scale long before it could buy scale of its own.
What she wants the next experiment to prove
By early 2026, Bitterfield was describing the next one to two years with the caution of a scientist and the deadlines of an operator. She expected first clinical data with collaborators, hoped more collaborations could be discussed publicly, and wanted to widen the platform's applications. Lindy is working on higher doses and optimized formulations, while exploring extended release and modes beyond subcutaneous delivery.
She is also frank about the constraint. Demand may be present, but a small company cannot accept every collaboration without expanding capacity. Growth, fundraising and execution must be balanced. This is the less photogenic side of a platform: every new use is also a staffing plan, a quality system, a manufacturing slot and a calendar full of decisions about what must wait.
The through-line in Bitterfield's public remarks is control. Control of protein behavior after water disappears. Control of a process as it moves from lab glassware toward manufacturing. Control of company growth when opportunity outruns capacity. Most of all, control of time. A technical founder can easily fall in love with the mechanism. Bitterfield keeps returning to the minutes outside it.
That may be the most stealable piece of the Lindy playbook. Choose a hard physical constraint. Explain it without hiding behind vocabulary. Let partners reveal where the technology is most useful. Finance the next proof, not the final fantasy. And when the science becomes difficult to narrate, return to the Tuesday. The water leaves the droplet. The dose occupies less space. If the clinical work succeeds, the rest of the day opens up.
Continue exploring